Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical Study is TJCS Eye Drops 0.05%(Cyclosporine ophthalmic
nano-emulsion) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group
12 weeks after treatment, each treatment group comparisons for evaluation of efficacy and
safety in Moderate to Severe Dry Eye Disease.